Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice results of a multicentric, retrospective study /
Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. I...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | SCIENTIFIC REPORTS
13 No. 1 |
| Tárgyszavak: | |
| doi: | 10.1038/s41598-023-44103-9 |
| mtmt: | 34199654 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/28568 |
| LEADER | 02762nab a2200385 i 4500 | ||
|---|---|---|---|
| 001 | publ28568 | ||
| 005 | 20231106094503.0 | ||
| 008 | 231106s2023 hu o 0|| Angol d | ||
| 022 | |a 2045-2322 | ||
| 024 | 7 | |a 10.1038/s41598-023-44103-9 |2 doi | |
| 024 | 7 | |a 34199654 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Váradi Melinda | |
| 245 | 1 | 0 | |a Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice |h [elektronikus dokumentum] : |b results of a multicentric, retrospective study / |c Váradi Melinda |
| 260 | |c 2023 | ||
| 300 | |a 11 | ||
| 490 | 0 | |a SCIENTIFIC REPORTS |v 13 No. 1 | |
| 520 | 3 | |a Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 2 | |a Kordáné Horváth Orsolya |e aut |
| 700 | 0 | 2 | |a Módos Orsolya |e aut |
| 700 | 0 | 2 | |a Fazekas Tamás |e aut |
| 700 | 0 | 2 | |a Grunewald Camilla M |e aut |
| 700 | 0 | 2 | |a Niegisch Günter |e aut |
| 700 | 0 | 2 | |a Krafft Ulrich |e aut |
| 700 | 0 | 2 | |a Grünwald Viktor |e aut |
| 700 | 0 | 2 | |a Hadaschik Boris |e aut |
| 700 | 0 | 2 | |a Olah Csilla |e aut |
| 700 | 0 | 2 | |a Maráz Anikó |e aut |
| 700 | 0 | 2 | |a Furka Andrea |e aut |
| 700 | 0 | 2 | |a Szűcs Miklós |e aut |
| 700 | 0 | 2 | |a Nyirády Péter |e aut |
| 700 | 0 | 2 | |a Szarvas Tibor |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/28568/1/s41598-023-44103-9.pdf |z Dokumentum-elérés |